RT Journal Article
T1 Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.
A1 Duarte-Salles, Talita
A1 Misra, Sandeep
A1 Stepien, Magdalena
A1 Plymoth, Amelie
A1 Muller, David
A1 Overvad, Kim
A1 Olsen, Anja
A1 Tjønneland, Anne
A1 Baglietto, Laura
A1 Severi, Gianluca
A1 Boutron-Ruault, Marie-Christine
A1 Turzanski-Fortner, Renee
A1 Kaaks, Rudolf
A1 Boeing, Heiner
A1 Aleksandrova, Krasimira
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Bamia, Christina
A1 Pala, Valeria
A1 Palli, Domenico
A1 Mattiello, Amalia
A1 Tumino, Rosario
A1 Naccarati, Alessio
A1 Bueno-de-Mesquita, H B As
A1 Peeters, Petra H
A1 Weiderpass, Elisabete
A1 Quirós, J Ramón
A1 Agudo, Antonio
A1 Sánchez-Cantalejo, Emilio
A1 Ardanaz, Eva
A1 Gavrila, Diana
A1 Dorronsoro, Miren
A1 Werner, Mårten
A1 Hemmingsson, Oskar
A1 Ohlsson, Bodil
A1 Sjöberg, Klas
A1 Wareham, Nicholas J
A1 Khaw, Kay-Tee
A1 Bradbury, Kathryn E
A1 Gunter, Marc J
A1 Cross, Amanda J
A1 Riboli, Elio
A1 Jenab, Mazda
A1 Hainaut, Pierre
A1 Beretta, Laura
AB We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between prediagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function, and α-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95% CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, ORmultivariable = 1.30; 95% CI, 1.14-1.48). The association was stronger among cases diagnosed within 2 years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC = 0.86). For cases diagnosed within 2 years, the combination of OPN and AFP was best able to predict HCC risk (AUC = 0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within 2 years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis. Cancer Prev Res; 9(9); 758-65. ©2016 AACR.
YR 2016
FD 2016-06-23
LK http://hdl.handle.net/10668/10210
UL http://hdl.handle.net/10668/10210
LA en
DS RISalud
RD Apr 10, 2025